An extended first-line indolent trial on Zevalin, Cell Therapeutics' radioimmunotherapy, found that patients with follicular B-cell non-Hodgkin's lymphoma who responded to first-line treatment exhibited continued improvement in progression-free survival after Zevalin consolidation therapy. The trial also showed that Zevalin consolidation treatment had no adverse effect on second-line therapies, including stem cell transplants among relapse patients.

Full Story:
RTT News

Related Summaries